2.24 -0.11 (-4.68%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 3.72 | 1-year : | 4.81 |
Resists | First : | 3.18 | Second : | 4.11 |
Pivot price | 2.42 | |||
Supports | First : | 1.67 | Second : | 1.39 |
MAs | MA(5) : | 2.22 | MA(20) : | 2.73 |
MA(100) : | 3.86 | MA(250) : | 5.86 | |
MACD | MACD : | -0.4 | Signal : | -0.4 |
%K %D | K(14,3) : | 30.4 | D(3) : | 27.9 |
RSI | RSI(14): 36.7 | |||
52-week | High : | 9.44 | Low : | 1.67 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MTEM ] has closed above bottom band by 41.2%. Bollinger Bands are 84.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 11 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 2.78 - 2.8 | 2.8 - 2.81 |
Low: | 2.08 - 2.09 | 2.09 - 2.1 |
Close: | 2.22 - 2.24 | 2.24 - 2.26 |
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
Thu, 28 Mar 2024
Molecular Templates secures $9.5 million in funding By Investing.com - Investing.com Nigeria
Thu, 28 Mar 2024
Molecular Templates announces $9.5M private placement offering (NASDAQ:MTEM) - Seeking Alpha
Thu, 28 Mar 2024
Molecular Templates Inc Raises Funds for Clinical Studies - TipRanks.com - TipRanks
Sat, 16 Mar 2024
Molecular Templates, Inc. (NASDAQ:MTEM) Short Interest Down 31.4% in February - Defense World
Fri, 15 Mar 2024
Molecular Templates Inc Faces BMS Collaboration Termination - TipRanks.com - TipRanks
Tue, 12 Mar 2024
Adage Capital Partners GP L.L.C. Reduces Holdings in Molecular Templates, Inc. (NASDAQ:MTEM) - Defense World
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 5 (M) |
Shares Float | 3 (M) |
Held by Insiders | 5.1 (%) |
Held by Institutions | 64.1 (%) |
Shares Short | 39 (K) |
Shares Short P.Month | 63 (K) |
EPS | -6.93 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 1.25 |
Profit Margin | -49.6 % |
Operating Margin | -75.6 % |
Return on Assets (ttm) | -20.1 % |
Return on Equity (ttm) | -478.9 % |
Qtrly Rev. Growth | 60.2 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 9.85 |
EBITDA (p.s.) | -3.5 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -55 (M) |
Levered Free Cash Flow | -32 (M) |
PE Ratio | -0.33 |
PEG Ratio | -0.3 |
Price to Book value | 1.77 |
Price to Sales | 0.22 |
Price to Cash Flow | -0.22 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |